Nature Communications (Mar 2021)
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
- Prasanna Jagannathan,
- Jason R. Andrews,
- Hector Bonilla,
- Haley Hedlin,
- Karen B. Jacobson,
- Vidhya Balasubramanian,
- Natasha Purington,
- Savita Kamble,
- Christiaan R. de Vries,
- Orlando Quintero,
- Kent Feng,
- Catherine Ley,
- Dean Winslow,
- Jennifer Newberry,
- Karlie Edwards,
- Colin Hislop,
- Ingrid Choong,
- Yvonne Maldonado,
- Jeffrey Glenn,
- Ami Bhatt,
- Catherine Blish,
- Taia Wang,
- Chaitan Khosla,
- Benjamin A. Pinsky,
- Manisha Desai,
- Julie Parsonnet,
- Upinder Singh
Affiliations
- Prasanna Jagannathan
- Department of Medicine, Stanford University
- Jason R. Andrews
- Department of Medicine, Stanford University
- Hector Bonilla
- Department of Medicine, Stanford University
- Haley Hedlin
- Quantitative Sciences Unit, Stanford University
- Karen B. Jacobson
- Department of Medicine, Stanford University
- Vidhya Balasubramanian
- Quantitative Sciences Unit, Stanford University
- Natasha Purington
- Quantitative Sciences Unit, Stanford University
- Savita Kamble
- Stanford Center for Clinical Research, Stanford University
- Christiaan R. de Vries
- Department of Medicine, Stanford University
- Orlando Quintero
- Department of Medicine, Stanford University
- Kent Feng
- Stanford Center for Clinical Research, Stanford University
- Catherine Ley
- Department of Medicine, Stanford University
- Dean Winslow
- Department of Medicine, Stanford University
- Jennifer Newberry
- Department of Emergency Medicine, Stanford University
- Karlie Edwards
- Department of Medicine, Stanford University
- Colin Hislop
- Department of Pediatrics, Stanford University
- Ingrid Choong
- Department of Pediatrics, Stanford University
- Yvonne Maldonado
- Eiger BioPharmaceuticals
- Jeffrey Glenn
- Department of Medicine, Stanford University
- Ami Bhatt
- Department of Medicine, Stanford University
- Catherine Blish
- Department of Medicine, Stanford University
- Taia Wang
- Department of Medicine, Stanford University
- Chaitan Khosla
- ChEM-H, Stanford University
- Benjamin A. Pinsky
- Department of Medicine, Stanford University
- Manisha Desai
- Quantitative Sciences Unit, Stanford University
- Julie Parsonnet
- Department of Medicine, Stanford University
- Upinder Singh
- Department of Medicine, Stanford University
- DOI
- https://doi.org/10.1038/s41467-021-22177-1
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 10
Abstract
Here the authors report the results of randomized, single-blind, placebocontrolled trial on the effects of a asingle subcutaneous dose of Peginterferon Lambda-1a (Lambda) in 120 outpatients with mild to moderate COVID-19, showing that while treatment is well tolerated it does not shorten the duration of SARS-CoV-2 viral shedding nor improves symptoms.
